Creatine

• Strength, power, and high-intensity exercise capacity (strongest evidence)
• Lean body mass gain during resistance training
• Muscle mass and strength preservation in older adults and sarcopenia (with resistance training)
• Cognitive support, mainly memory in older adults and under acute stress like sleep deprivation (weaker, mixed)
• Depression adjunct alongside an SSRI (preliminary, one main RCT)
• Recovery, glycogen replenishment, and cell hydration support

Creatine is a tripeptide-like compound (formed from arginine, glycine, and methionine) that the body uses to recycle ATP, the cellular energy currency, during short, high-intensity efforts. Roughly ninety-five percent of body creatine is stored in skeletal muscle, primarily as phosphocreatine. When a muscle fiber consumes ATP faster than aerobic respiration can replace it (the first ten to twenty seconds of any maximal effort), phosphocreatine donates its phosphate to ADP, regenerating ATP almost instantaneously. Supplemental creatine increases muscle phosphocreatine stores by roughly ten to forty percent, depending on baseline, sex, and diet. The result is more available "instant energy" for short repeated bouts, the biochemical basis for the lifting, sprinting, and sport-specific performance benefits. The brain story is more recent and more subtle. The brain uses creatine for the same ATP-recycling function, particularly under metabolic stress, sleep deprivation, hypoxia, hypoglycemia, and intense cognitive load. Brain creatine stores are smaller than muscle stores and turn over more slowly, which is why brain-targeted effects typically require higher doses (10g+/day) or longer dosing periods (4-8 weeks) than the standard 5g/day muscle protocol. Emerging trial evidence for cognition, mood, and possibly Parkinson's-related neurodegeneration is built on this mechanism. Vegetarians and vegans have meaningfully lower baseline creatine stores (because dietary creatine comes from meat and fish), which is why they consistently show the largest performance and cognitive responses to supplementation.

The simplest evidence-based protocol: 5 grams of creatine monohydrate daily, taken at any consistent time. The "loading phase" (20g/day split across four doses for 5-7 days, then 3-5g/day maintenance) accelerates muscle saturation to about a week instead of about a month, but is not required and is more likely to cause GI upset. Timing relative to workouts has been studied extensively; no consistent superiority for pre- versus post-workout has emerged. Taking with carbohydrates (~50g) or carbs-and-protein modestly enhances uptake via insulin-mediated transport, but this is a small effect that most users do not need to engineer. Consistency matters more than timing, daily uninterrupted use for at least 4 weeks is what produces the measurable performance effect.

Timing

Daily, consistent, pre/post workout difference is trivial. Off days matter as much as training days.

Dose

3g/day saturates the average male muscle compartment within ~28 days. 5g/day is more reliable and remains within the safety envelope. Women and larger users may want 8-10g/day for brain endpoints.

Loading

Optional. Speeds up muscle saturation by ~3 weeks. Often causes GI upset; rarely worth it for non-athletes.

Food state

With or without food. Carbs modestly enhance uptake; most users do not need to manage this actively.

Hydration

Take with adequate water (one full glass minimum). Hydration concerns are largely mythical, but water uptake by muscle does increase modestly.

Cycling

Not necessary. No clinical evidence that the body downregulates or develops tolerance to oral creatine.

Skipped day

One missed day is irrelevant. Muscle creatine washes out slowly (weeks, not days). Resume normally.

Discontinuation

Effects fade gradually over 4-6 weeks as muscle stores normalize. No withdrawal or rebound.

• Creatine Monohydrate

  Rating: gold

  The form used in essentially every clinical trial of consequence. Cheapest per gram, most studied, most reliable. Creapure® (German-manufactured by AlzChem) is the most-tested branded source for purity. Generic monohydrate from third-party-tested manufacturers is functionally equivalent at meaningfully lower cost.

• Micronized Creatine Monohydrate

  Rating: good

  Smaller particle size for better mixability in water, eliminates the gritty texture of standard monohydrate without changing absorption or efficacy. A reasonable upcharge for users who mix in cold water.

• Creatine HCl

  Rating: emerging

  Marketed for "better absorption" and "no loading needed." The absorption claim has limited independent support; oral monohydrate at 5g/day already achieves near-maximum muscle saturation within ~4 weeks without loading. Substantially more expensive per gram of active creatine.

• Kre-Alkalyn (Buffered)

  Rating: caution

  pH-buffered formulation marketed as more stable in stomach acid. Independent comparative trials (Jagim 2012) found no superiority over monohydrate on muscle creatine content, strength, or body composition. Pays a premium for a marketing claim.

• Creatine Ethyl Ester

  Rating: caution

  Older marketed form claiming improved bioavailability. Spillane 2009 trial found ethyl ester actually produced lower muscle creatine elevation than monohydrate, the opposite of marketing claims. Largely discredited form.

• Creatine Malate / Citrate / Pyruvate

  Rating: emerging

  Various salt forms; modest claimed bioavailability advantages without compelling head-to-head trial evidence for clinical superiority. Reasonable if monohydrate causes GI issues; generally an expensive way to deliver less creatine per dose.

• Resistance-training adults

  Strength of evidence for this group: strong

  The original use case. Roughly 10-15% strength improvement and 1-2kg additional lean mass versus training alone, averaged across meta-analyses. Effects are reproducible, dose-dependent, and present within 4-8 weeks of consistent use.

• Older adults (60+) with sarcopenia risk

  Strength of evidence for this group: strong

  Creatine plus resistance training meaningfully outperforms training alone for lean mass and functional outcomes (chair stand, gait speed, grip strength). The case may be stronger here than in young athletes because baseline creatine stores are typically lower.

• Vegetarians and vegans

  Strength of evidence for this group: strong

  Lowest baseline muscle creatine stores of any cohort (dietary creatine comes from meat and fish). Consistently show the largest cognitive and performance responses in trials. The single best-evidenced supplement for this population.

• Women across the lifespan

  Strength of evidence for this group: modest

  Historically under-studied and under-dosed in trials. Emerging evidence supports performance and cognitive benefits at standard doses; some researchers (Roschel, Smith-Ryan) argue women may benefit from higher per-kg doses (~0.1g/kg, often 8-10g) for muscle and brain endpoints. Special interest in perimenopause and postmenopause for sarcopenia.

• Sleep-deprived knowledge workers

  Strength of evidence for this group: modest

  The cognitive-under-stress case. Multiple trials show cognitive performance preservation under sleep deprivation at higher doses (10-20g/day, often as a single pre-task dose). Most reproducible cognitive use case in non-vegetarian users.

• Adults with mood concerns (preliminary)

  Strength of evidence for this group: cautious

  Multiple trials suggest creatine as an SSRI adjunct may shorten time to response in major depression, particularly in women. Not yet a routine clinical use; the case is built on small trials and adjunct rather than monotherapy.

• Pre-existing renal disease

  Strength of evidence for this group: cautious

  The kidney concern is largely a myth in healthy users, but pre-existing renal impairment is a different scenario. Coordinate with nephrology rather than self-supplementing.

• Caffeine

  Interaction: neutral

  Older trials suggested caffeine might blunt creatine's effects; modern controlled studies have not reproduced this. Most current evidence is that the combination is neutral to mildly synergistic for short-duration athletic performance. Standard pre-workout combinations are fine.

• Carbohydrates (~50g)

  Interaction: synergy

  Modest insulin-mediated improvement in muscle creatine uptake. Most beneficial during initial loading or in low-carb users. The effect is small and most consumers do not need to engineer this.

• Beta-Alanine

  Interaction: synergy

  Complementary mechanisms (creatine: phosphocreatine recycling; beta-alanine: muscle carnosine buffering for slightly longer-duration efforts). Stack reliably outperforms either alone for high-intensity training.

• Protein / amino acids

  Interaction: synergy

  Standard post-workout combination. The protein supports muscle protein synthesis; creatine supports phosphocreatine restoration. Reliable and well-evidenced.

• HMB

  Interaction: neutral

  Often co-marketed but limited evidence of meaningful synergy in trained users. HMB's evidence base is weaker than creatine's; pairing rarely changes the equation.

• Pre-existing kidney disease

  Interaction: avoid

  Self-supplementing creatine without nephrology guidance is not appropriate in users with pre-existing renal impairment. The healthy-population safety data does not transfer.

• Diuretics

  Interaction: caution

  Theoretical hydration interaction at high doses. Most users on diuretics tolerate standard creatine doses; worth a clinician check.

Look for: NSF Certified for Sport or Informed Sport seal, USP verification, or current Certificate of Analysis. Creapure® on the label is a positive signal (German pharmaceutical-grade source). Avoid: proprietary blends that don't disclose creatine content, "loaded" pre-workout formulas where creatine dose is unclear, and anything claiming dramatic superiority over monohydrate without head-to-head trial citations.

Research published from: France.

Michel-Eugène Chevreul isolated creatine from meat extract at the Muséum National d'Histoire Naturelle in Paris in 1832, naming it after the Greek kreas (flesh). Justus von Liebig confirmed its presence in mammalian muscle in 1847. The pharmacokinetic foundation for modern supplementation came from Chanutin and Guzman in 1926, who established human creatine retention and excretion patterns. For most of the twentieth century creatine remained a biochemistry curiosity rather than a supplement. Modern creatine supplementation traces to a specific paper: Harris, Söderlund, and Hultman, "Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation," published in Clinical Science in 1992. The Karolinska group demonstrated that oral creatine could meaningfully increase muscle phosphocreatine, particularly in baseline-depleted individuals. Within two years, the 1992 Barcelona and 1996 Atlanta Olympic Games featured public discussion of creatine's role in elite track and weightlifting performance. The commercial supplement industry exploded in the mid-1990s. The brain-creatine line emerged from a different scientific lineage: pediatric inborn-errors-of-metabolism research on creatine deficiency syndromes (GAMT deficiency, AGAT deficiency) demonstrated that brain creatine was essential for normal cognitive development. Rae's 2003 vegetarian cognitive trial established the supplement-side hypothesis. The 2010s and 2020s have built a substantial brain-creatine literature, culminating in the current understanding that brain-targeted dosing differs meaningfully from muscle-targeted dosing.

1. 1832Chevreul isolates creatine from meat extract at the Paris Natural History Museum
2. 1847Justus von Liebig confirms creatine in mammalian muscle
3. 1926Chanutin and Guzman establish human pharmacokinetics, basis for modern dosing
4. 1992Harris, Söderlund, Hultman (Karolinska): foundational supplementation trial in Clinical Science
5. 1996Olympic-era commercial expansion; mainstream awareness in strength sports
6. 2003Rae trial establishes vegetarian cognitive benefit; brain-creatine research line begins
7. 2017Chilibeck meta-analysis on sarcopenia, strongest case for healthy aging
8. 2021Antonio comprehensive safety review across three decades
9. 2022Forbes brain creatine review formalizes the dose-stratification for cognitive endpoints
10. 2023Candow age-and-sex stratification establishes higher-dose case for women
11. 2024EFSA reaffirms health claim for physical performance

• Optimal dose for women across different reproductive-stage cohorts, perimenopause and postmenopause specifically are under-studied.
• Whether higher doses (10-20g/day) for brain-targeted endpoints carry any long-term concerns not seen at the standard 3-5g muscle-targeted dose.
• Whether the SSRI-adjunct depression signal will replicate in larger trials and become a standard psychiatric recommendation.
• Whether long-term creatine use (decades) in healthy adults has any cumulative effects positive or negative, most surveillance is 5-15 years.
• Whether the Parkinson's and Huntington's neuroprotection signals (mixed in trials) will resolve into a clinical indication.
• Whether the apparent vegetarian-baseline-amplification of effects extends to other under-supplemented amino acid pathways.

Universally available globally as a dietary supplement. Among the cheapest evidence-validated supplements per effective dose ($0.10-$0.30/day at standard 5g). GRAS status in the US. No regulatory restrictions in any major market. The European Food Safety Authority has approved a health claim for creatine and physical performance, one of the few supplement-class health claims to clear EFSA review. Major retailers (Costco, Amazon, supermarket chains) all carry monohydrate at commodity pricing.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Form

Tripeptide-like (arginine, glycine, methionine)

Body storage

~95% in skeletal muscle as phosphocreatine

Standard dose

3-5g/day monohydrate

Higher dose for brain

10-20g/day

Loading (optional)

20g/day x 5-7 days

Saturation time

~4 weeks at 5g/day

What follows is unfinished work on our side, not a finding about Creatine. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.